Largest Recorded Outbreak of Blastomycosis in the U.S. Occurred in Michigan
On Dec. 31, 2024, the U.S. Centers for Disease Control and Prevention released a study of the largest…
-
-
Oregon announces Recall of Pet Food Due to HPAI Contamination
On Dec. 26, 2024, the Oregon Department of Agriculture (ODA) announced it is alerting pet owners that samples…
-
Karmanos Cancer Institute First in the World to use FDA-approved Radiofrequency Electromagnetic Device to Treat Liver Cancer
On Dec. 18, 2024, the Barbara Ann Karmanos Cancer Institute announced that the new TheraBionic P1 device, an…
-
Outbreak of Blastomycosis reported in Michigan Mill workers
On Feb. 28, 2023, Public Health Delta & Menominee Counties (PHDM) was alerted to three cases of atypical…
-
Pfizer to supply global fund up to 6 million PAXLOVID treatment courses for low-and-middle-income countries
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
-
Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
-
Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
-
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
-
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
-
Pfizer provided U.S. Government with additional 10 million treatment courses of oral therapy to help combat COVID-19
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
-
Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
-
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
-
Pfizer provided U.S. Government with 10 million treatment courses of oral antiviral candidate to help combat COVID-19
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
-
Pfizer submitted Emergency Use Authorization for novel COVID-19 oral antiviral candidate
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
-
Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
-
The FDA approved non-statin drug to treat high cholesterol
On Feb. 21, 2020, the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral,…
-
Karmanos Cancer Institute was awarded the President’s Trophy for second year in a row by McLaren Health Care
On Jan. 16, 2020, the Barbara Ann Karmanos Cancer Institute received the President’s Trophy for the second year…
-
Karmanos Cancer Institute received the 2020 Women’s Choice Award
On Dec. 23, 2019, the Barbara Ann Karmanos Cancer Institute received the 2020 Women’s Choice Award as one…
-
Karmanos Cancer Institute awarded President’s Trophy by McLaren Health Care system
On Jan. 24, 2019, the Barbara Ann Karmanos Institute received the President’s Trophy from McLaren Health Care system,…
-
Karmanos Cancer Institute and Wayne State University awarded prestigious LAPS grant
On Dec. 20, 2018, the Karmanos Cancer Institute and Wayne State University were awarded the prestigious LAPS Grant…
-
Karmanos Morey Cancer Center recognized by the American Society of Clinical Oncology with the QOPI Certification Program
On Dec. 17, 2018, the Karmanos Morey Cancer Center was recognized by the American Society of Clinical Oncology…
-
The University of Michigan Cancer Center was renamed the Rogel Cancer Center
In 2018, the University of Michigan Cancer Center was renamed the Rogel Cancer Center in recognition of a…
-
Karmanos researcher Patricia LoRusso appointed co-leader of the Stand Up To Cancer Dream Team
On Dec. 14, 2011, Patricia M. LoRusso, D.O., of the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan;…
-
Karmanos Cancer Institute became Michigan’s first and only independent hospital exclusively for cancer patients
On Dec. 1, 2005, the Barbara Ann Karmanos Cancer Institute became Michigan’s first and only independent hospital exclusively…
-
Biotechnology | Diagnostics | Disease | Environmental | NIH | Non-Profit Research | Oncology | Therapeutics
The National Center for Vermiculite and Asbestos-Related Cancers was established
Apr. 14, 2004, the National Center for Vermiculite and Asbestos-Related Cancers was established in Michigan in response to…
-
Karmanos Institute and JP McCarthy Cord Stem Cell Bank founded
In 2001, The J.P. McCarthy Cord Stem Cell Bank at the Karmanos Cancer Institute was founded as a…
-
Human immunogenetics professor Dr. Gloria M. Dunston founded the National Human Genome Center at Howard University
In 2001, human immunogenetics professor Dr. Gloria M. Dunston founded the National Human Genome Center at Howard University….
-
The Hudson-Webber Cancer Research Center opened
In 1999, the Hudson-Webber Cancer Research Center opened to serve as a ‘translational’ research facility, bridging the gaps…
-
The University of Michigan Rogel Cancer Center received Comprehensive NCI designation
In 1991, the University of Michigan Rogel Cancer Center received National Cancer Institute (NCI) comprehensive center designation. The…
-
The world’s first superconducting cyclotron built to treat cancer was installed in Gershenson Radiation Oncology Center
In 1991, the world’s first superconducting cyclotron built to treat cancer was installed at the Gershenson Radiation Oncology…
